944 reports of this reaction
1.9% of all TAPENTADOL HYDROCHLORIDE reports
#7 most reported adverse reaction
DRUG WITHDRAWAL SYNDROME NEONATAL is the #7 most commonly reported adverse reaction for TAPENTADOL HYDROCHLORIDE, manufactured by Collegium Pharmaceutical, Inc.. There are 944 FDA adverse event reports linking TAPENTADOL HYDROCHLORIDE to DRUG WITHDRAWAL SYNDROME NEONATAL. This represents approximately 1.9% of all 50,606 adverse event reports for this drug.
TAPENTADOL HYDROCHLORIDE has an overall safety score of 92 out of 100. Patients taking TAPENTADOL HYDROCHLORIDE who experience drug withdrawal syndrome neonatal should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG WITHDRAWAL SYNDROME NEONATAL is a less commonly reported adverse event for TAPENTADOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to drug withdrawal syndrome neonatal, the following adverse reactions have been reported for TAPENTADOL HYDROCHLORIDE:
The following drugs have also been linked to drug withdrawal syndrome neonatal in FDA adverse event reports:
DRUG WITHDRAWAL SYNDROME NEONATAL has been reported as an adverse event in 944 FDA reports for TAPENTADOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG WITHDRAWAL SYNDROME NEONATAL accounts for approximately 1.9% of all adverse event reports for TAPENTADOL HYDROCHLORIDE, making it a notable side effect.
If you experience drug withdrawal syndrome neonatal while taking TAPENTADOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.